Study #2022-0751
An Open-label phase 1b study of E7386 in combination with other Anticancer Drug(s) in subjects with solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
E7386, Lenvatinib, Doxorubicin, Paclitaxel
Description
The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s), and to determine the optimal dose of E7386 in combination with lenvatinib in endometrial carcinoma (EC) (for EC Dose Optimization Part only).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms
Study phase:
Physician name:
Pamela Soliman
Department:
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.